BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1494 related articles for article (PubMed ID: 18391108)

  • 1. Death without prior appropriate implantable cardioverter-defibrillator therapy: a competing risk study.
    Koller MT; Schaer B; Wolbers M; Sticherling C; Bucher HC; Osswald S
    Circulation; 2008 Apr; 117(15):1918-26. PubMed ID: 18391108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical prediction model for death prior to appropriate therapy in primary prevention implantable cardioverter defibrillator patients with ischaemic heart disease: the FADES risk score.
    van Rees JB; Borleffs CJ; van Welsenes GH; van der Velde ET; Bax JJ; van Erven L; Putter H; van der Bom JG; Schalij MJ
    Heart; 2012 Jun; 98(11):872-7. PubMed ID: 22581736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers].
    Marín F; Gimeno JR; Payá E; García-Alberola A; Pérez-Alvarez L; Fernández X; de la Morena G; Sogorb F; Castro-Beiras A; Valdés M; Martínez JG; Monserrat L
    Rev Esp Cardiol; 2006 Jun; 59(6):537-44. PubMed ID: 16790196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers Of Ventricular Arrhythmias (TOVA) study.
    Whang W; Mittleman MA; Rich DQ; Wang PJ; Ruskin JN; Tofler GH; Muller JE; Albert CM;
    Circulation; 2004 Mar; 109(11):1386-91. PubMed ID: 14993132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rates and predictors of appropriate implantable cardioverter-defibrillator therapy delivery: results from the EVADEF cohort study.
    Otmani A; Trinquart L; Marijon E; Lavergne T; Waintraub X; Lepillier A; Chatellier G; Le Heuzey JY;
    Am Heart J; 2009 Aug; 158(2):230-237.e1. PubMed ID: 19619699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time-dependence of appropriate implantable defibrillator therapy in patients with ischemic cardiomyopathy.
    Alsheikh-Ali AA; Homer M; Maddukuri PV; Kalsmith B; Estes NA; Link MS
    J Cardiovasc Electrophysiol; 2008 Aug; 19(8):784-9. PubMed ID: 18284493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary prevention of sudden cardiac death by implantable cardioverter-defibrillator therapy in Chinese patients with heart failure: a single-center experience.
    Chen TB; Cheng KA; Gao P; Cheng ZW; Fan JB; Jiang XC; Fang Q
    Chin Med J (Engl); 2010 Apr; 123(7):848-51. PubMed ID: 20497676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Left ventricular ejection fraction and absence of ACE inhibitor/angiotensin II receptor blocker predicts appropriate defibrillator therapy in the primary prevention population.
    Obeyesekere MN; Chan W; Stub D; Prabhu S; Teo EP; Toogood G; Mariani J; Broughton A; Kistler PM
    Pacing Clin Electrophysiol; 2010 Jun; 33(6):696-704. PubMed ID: 20059719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Competing risk analysis of cause-specific mortality in patients with an implantable cardioverter-defibrillator: The EVADEF cohort study.
    Marijon E; Trinquart L; Otmani A; Waintraub X; Kacet S; Clémenty J; Chatellier G; Le Heuzey JY;
    Am Heart J; 2009 Feb; 157(2):391-397.e1. PubMed ID: 19185651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [14-year experience with implantable cardioverter/defibrillators: determination of prognosis and discharge behavior].
    Vester EG; Dees H; Dobran I; Hennersdorf M; Perings C; Heydthausen M; Winter J; Strauer BE
    Z Kardiol; 2000; 89 Suppl 3():194-205. PubMed ID: 10810803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sudden death prior to pediatric heart transplantation: would implantable defibrillators improve outcome?
    Rhee EK; Canter CE; Basile S; Webber SA; Naftel DC
    J Heart Lung Transplant; 2007 May; 26(5):447-52. PubMed ID: 17449412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Italian Implantable Cardioverter-Defibrillator Registry. A survey of the national activity during the years 2001-2003.
    Proclemer A; Ghidina M; Cicuttini G; Gregori D; Fioretti PM
    Ital Heart J; 2005 Mar; 6(3):272-80. PubMed ID: 15875520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implantable cardioverter defibrillator therapy: ten years experience in a medical center.
    Chen TE; Wang CC; Chang SH; Yeh SJ; Wu D
    Chang Gung Med J; 2008; 31(1):81-90. PubMed ID: 18419057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of appropriate defibrillator therapy in heart failure patients treated with cardiac resynchronization therapy.
    Soliman OI; Theuns DA; van Dalen BM; Vletter WB; Nemes A; Jordaens LJ; Balk AH; Ten Cate FJ; Geleijnse ML
    Am J Cardiol; 2010 Jan; 105(1):105-11. PubMed ID: 20102900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of ventricular tachyarrhythmias occurring in ischemic versus nonischemic patients implanted with a biventricular cardioverter-defibrillator for primary or secondary prevention of sudden death.
    Boriani G; Gasparini M; Lunati M; Santini M; Landolina M; Vincenti A; Curnis A; Bocchiardo M; Padeletti L; Biffi M; Allaria L; Denaro A;
    Am Heart J; 2006 Sep; 152(3):527.e1-11. PubMed ID: 16923425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival and appropriate device interventions in recipients of cardioverter defibrillators implanted for the primary versus secondary prevention of sudden cardiac death.
    Stockburger M; Krebs A; Nitardy A; Habedank D; Celebi O; Knaus T; Dietz R
    Pacing Clin Electrophysiol; 2009 Mar; 32 Suppl 1():S16-20. PubMed ID: 19250084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II).
    Singh JP; Hall WJ; McNitt S; Wang H; Daubert JP; Zareba W; Ruskin JN; Moss AJ;
    J Am Coll Cardiol; 2005 Nov; 46(9):1712-20. PubMed ID: 16256874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the implantable defibrillator among elderly patients with a history of life-threatening ventricular arrhythmias.
    Healey JS; Hallstrom AP; Kuck KH; Nair G; Schron EP; Roberts RS; Morillo CA; Connolly SJ
    Eur Heart J; 2007 Jul; 28(14):1746-9. PubMed ID: 17283003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 75.